keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/28211081/h3f3a-mutation-in-giant-cell-tumour-of-the-bone-is-detected-by-immunohistochemistry-using-a-monoclonal-antibody-against-the-g34w-mutated-site-of-the-histone-h3-3-variant
#1
Julian Lüke, Alexandra von Baer, Jordan Schreiber, Christoph Lübbehüsen, Thomas Breining, Kevin Mellert, Ralf Marienfeld, Markus Schultheiss, Peter Möller, Thomas Fe Barth
AIMS: Giant cell tumour of bone (GCTB) is a neoplasm predominantly of long bones characterised by the H3F3A mutation G34W. Conventional diagnostic is challenged by the tumour's giant cell-rich morphology, which overlaps with other giant cell containing lesions of the bone. Recently, a monoclonal antibody specific for the H3F3A mutation has been generated. Our aim was to test this antibody on a cohort of giant cell containing lesions. METHODS AND RESULTS: We used the antibody for analysis of 22 H3F3A-mutated GCTB, including two patients with recurrences; for comparison we analysed a cohort of 36 H3F3A-wild-type giant cell-rich lesions of the bone and soft tissue, containing one brown tumour, six aneurysmal bone cysts, six chondroblastomas, five non-ossifying-fibromas, two fibrous dysplasias, nine tenosynovial giant cell tumours, one giant cell-rich sarcoma and six osteosarcomas...
February 17, 2017: Histopathology
https://www.readbyqxmd.com/read/28210776/cost-effectiveness-of-denosumab-versus-oral-alendronate-for-elderly-osteoporotic-women-in-japan
#2
T Mori, C J Crandall, D A Ganz
: We constructed a Markov microsimulation model among hypothetical cohorts of community-dwelling elderly osteoporotic Japanese women without prior hip or vertebral fractures over a lifetime horizon. Compared with weekly oral alendronate for 5 years, denosumab every 6 months for 5 years is cost-saving or cost-effective at a conventionally accepted threshold. INTRODUCTION: The objective of the study was to examine the cost-effectiveness of subcutaneous denosumab every 6 months for 5 years compared with weekly oral alendronate for 5 years in Japan...
February 17, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28208958/radiological-and-histopathological-outcome-of-giant-cell-tumor-of-femur-with-denosumab-treatment-a-case-report
#3
Preethi Dileep Menon, R Krishnakumar, Annie Jojo
Giant Cell Tumour of Bone (GCTB) is a benign but locally aggressive osteolytic skeletal neoplasm of young adults consisting of giant cells expressing RANK (Receptor Activator of Nuclear Factor-κB) and mesenchymal spindle-like stromal cells expressing RANKL (RANK ligand). The interaction of these cells leads to bone resorption. Recently, the RANKL inhibitor, denosumab, has demonstrated activity against giant-cell tumours. The current article reports a case of a Giant cell tumour of left distal femur with pathological fracture...
December 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28203164/successful-treatment-of-advanced-primary-cutaneous-apocrine-carcinoma-on-the-scrotum-with-systemic-chemotherapy-and-radiotherapy-followed-by-denosumab
#4
Sadanori Furudate, Taku Fujimura, Akira Tsukada, Yota Sato, Takanori Hidaka, Kayo Tanita, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba
Primary cutaneous apocrine carcinoma (PCAC) is a rare and highly aggressive cutaneous adnexal type of tumor that has a high metastasis rate and a poor prognosis. Although there are several case reports describing the successful treatment of PCAC with chemoradiotherapy or molecular targeting therapy, no standard therapy for the treatment of advanced PCAC has been established yet. Since receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed in cancers of apocrine origin, leading to immunosuppression at the tumor site, we hypothesized that targeting RANKL with denosumab might be useful for the treatment of PCAC...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28188337/giant-cell-tumor-of-the-bone-aggressive-case-initially-treated-with-denosumab-and-intralesional-surgery
#5
Donald von Borstel, Roberto A Taguibao, Nicholas A Strle, Joseph E Burns
Giant cell tumor of the bone (GCTB) is a locally aggressive benign tumor, which has historically been treated with wide surgical excision. We report a case of a 29-year-old male with histology-proven GCTB of the distal ulna. The initial imaging study was a contrast-enhanced magnetic resonance imaging (MRI) examination of the left wrist, which was from an outside facility performed before presenting to our institution. On the initial MRI, the lesion had homogenous T2-hyperintense and T1-hypointense signal with expansive remodeling of the osseous contour...
April 2017: Skeletal Radiology
https://www.readbyqxmd.com/read/28188332/adjudication-of-osteonecrosis-of-the-jaw-in-phase-iii-randomized-controlled-trials-of-denosumab-a-systematic-review
#6
REVIEW
Paul de Boissieu, L Kanagaratnam, R Mahmoudi, A Morel, M Dramé, T Trenque
PURPOSE: Denosumab (an anti RANKL antibody) is known to be associated with an increased risk for osteonecrosis of the jaw (ONJ). Due to the variety of clinical presentation, many ONJ definitions are used. Evaluation of ONJ's frequency during phase III randomized controlled trials (RCTs) is crucial to assess benefit-risk ratio. We verified that phase III RCTs involving denosumab reported the definition of ONJ used. METHODS: We systematically searched in Central, Medline, Cochrane, and Scopus, until 31 August 2015...
February 10, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28183253/optimal-management-of-prostate-cancer-based-on-its-natural-clinical-history
#7
Gaetano Facchini, Francesco Perri, Gabriella Misso, Carmine D Aniello, Giuseppina Della Vittoria Scarpati, Sabrina Rossetti, Chiara Della Pepa, Salvatore Pisconti, Gerhard Unteregger, Alessia Cossu, Michele Caraglia, Massimiliano Berretta, Carla Cavaliere
Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnostic techniques, a not small percentage of prostate tumours is still diagnosed in advanced stage. It is now clear that prostate cancer passes through distinct phases during its natural history, starting from an initial phase, in which the disease has a locoregional extent, until a very late phase when it becomes refractory to hormone therapy. It is important to distinguish between local disease, in which tumor may be considered localized in the gland and a systemic disease characterized by high tumor burden and/or dissemination of circulating tumour cells...
February 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28179326/pathogenesis-of-osteosclerotic-change-following-treatment-with-an-antibody-against-rankl-for-giant-cell-tumour-of-the-bone
#8
Mamer Rosario, Akihiko Takeuchi, Norio Yamamoto, Katsuhiro Hayashi, Shinji Miwa, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Hisaki Aiba, Yoshikazu Tanzawa, Hideki Murakami, Hiroyuki Tsuchiya
BACKGROUND: Giant cell tumours (GCTs) of the bone are intermediate tumours that are locally aggressive. Denosumab, an antibody against receptor activator of nuclear factor kappa-B ligand (RANKL), was recently developed; however, it induces osteosclerotic change through an unknown mechanism. We determined whether osteosclerotic change could be induced by neoplastic stromal cells of giant cell tumours (GCTs). PATIENTS AND METHODS: Participants included four patients with GCT of the bone who were treated with neoadjuvant denosumab...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28169118/bone-health-and-bone-targeted-therapies-for-prostate-cancer-a-programme-in-evidence-based-care-cancer-care-ontario-clinical-practice-guideline
#9
S M H Alibhai, K Zukotynski, C Walker-Dilks, U Emmenegger, A Finelli, S C Morgan, S J Hotte, E Winquist
AIMS: To make recommendations with respect to bone health and bone-targeted therapies in men with prostate cancer. MATERIALS AND METHODS: A systematic review was carried out by searching MEDLINE, EMBASE and the Cochrane Library from inception to January 2016. Systematic reviews and randomised-controlled trials were considered for inclusion if they involved therapies directed at improving bone health or outcomes such as skeletal-related events, pain and quality of life in patients with prostate cancer either with or without metastases to bone...
February 3, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28168064/hypercalcemia-of-malignancy-in-thymic-carcinoma-evolving-mechanisms-of-hypercalcemia-and-targeted-therapies
#10
Cheng Cheng, Jose Kuzhively, Sanford Baim
Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM). Case Description. We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy...
2017: Case Reports in Endocrinology
https://www.readbyqxmd.com/read/28164066/giant-cell-tumor-developing-in-paget-s-disease-of-bone-a-case-report-with-review-of-literature
#11
Vivek Verma, Ajay Puri, Sanket Shah, Bharat Rekhi, Ashish Gulia
INTRODUCTION: Paget's disease of bone (PDB) is a disease of elderly characterized by disorganized bone remodeling. Development of secondary neoplasm in PDB is a known but rare phenomenon. Development of giant cell tumor in PDB (GCT-PDB) is extremely rare, and little is known about its etiopathogenesis and management. We present a case report of such a development with a review of the literature and the role of various new modalities of treatment available in the management of this rare condition...
September 2016: Journal of Orthopaedic Case Reports
https://www.readbyqxmd.com/read/28152965/early-experience-with-puerto-rico-effective-use-management-of-bone-agents
#12
Dinah Faith Q Huff, Lourdes Feliciano, Charles L Bennett, Kevin Knopf, William J Hrushesky, Anna DiMarco, Michael Baum
: 130 Background: Oncology Analytics is a cancer care decision support group recently entering the Puerto Rican cancer care marketplace. Bone agents are used in metastatic cancer management to delay the progression of lytic bone metastases. These agents are also used for the treatment of demonstrated osteoporosis with bone densitometry (DEXA scan). Oncology Analytics has found these agents are sometimes used in the absence of lytic metastases or osteoporosis. When this is discussed with treating physicians, practice patterns promptly improve...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28149927/the-relationship-of-industry-payments-to-prescribing-behavior-a-study-of-degarelix-and-denosumab
#13
Jathin Bandari, Robert M Turner, Bruce L Jacobs, David Canes, Ali Moinzadeh, Benjamin J Davies
INTRODUCTION: The influence of financial ties to pharmaceutical companies remains controversial. We aimed to assess a potential relationship between pharmaceutical payments and prescription patterns for degarelix and denosumab. MATERIALS AND METHODS: Medicare Provider Utilization and Payment Data: Physician and Other Supplier Public Use File (Medicare B) data containing 2012 claims compared to OpenPayments (Sunshine Act) data for the second half of 2013. Urologists and medical oncologists who billed Medicare for degarelix or denosumab were cross referenced in both databases and payments were aggregated into a consolidated dataset...
January 2017: Urology Practice
https://www.readbyqxmd.com/read/28144701/observations-following-discontinuation-of-long-term-denosumab-therapy
#14
M R McClung, R B Wagman, P D Miller, A Wang, E M Lewiecki
: Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upon stopping denosumab should be considered. INTRODUCTION: This study aimed to understand osteoporosis management strategies during a 1-year observational follow-up after up to 8 years of denosumab treatment in a phase 2 study...
January 31, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28131133/combined-pharmacologic-therapy-in-postmenopausal-osteoporosis
#15
REVIEW
Yang Shen, Dona L Gray, Dorothy S Martinez
Antiresorptive agents for treating postmenopausal osteoporosis include selective estrogen receptor modulator (SERM), bisphosphonates and denoumab. Teriparatide is the only Food and Drug Administration-approved anabolic agent. Synergistic effects of combining teriparatide with an antiresorptive agent have been proposed and studied. This article reviews the trial designs and the outcomes of combination therapies. Results of the combination therapy for teriparatide and bisphosphonates were mixed; while small increases of bone density were observed in the combination therapy of teriparatide and estrogen/SERM and that of teriparatide and denosumab...
March 2017: Endocrinology and Metabolism Clinics of North America
https://www.readbyqxmd.com/read/28131131/drug-related-adverse-events-of-osteoporosis-therapy
#16
REVIEW
Moin Khan, Angela M Cheung, Aliya A Khan
Postmenopausal osteoporosis is associated with microarchitectural deterioration and increased risk of fracture. Osteoporosis therapy effectively reduces the risk of vertebral, nonvertebral, and hip fracture and has been associated with increased survival. Currently approved treatments for osteoporosis include bisphosphonates, denosumab, selective estrogen receptor modulators, and teriparatide. This article reviews the adverse events of therapy associated with these medical interventions. Hormone replacement therapy is not included, because it is no longer indicated for the treatment of osteoporosis in all countries...
March 2017: Endocrinology and Metabolism Clinics of North America
https://www.readbyqxmd.com/read/28123120/-drug-selection-and-treatment-goal-in-osteoporosis-therapy
#17
Mika Yamauchi, Toshitsugu Sugimoto
The goal of treatment for osteoporosis is to reduce the risk of fracture. Achieving effective reductions in the risk of fracture requires evidence-based drug selection and careful consideration of patient background, including concomitant diseases and drug adherence. Selective estrogen receptor modulators(SERM)and active vitamin D3 such as eldecalcitol are well indicated in early menopausal women with no history of fragility fractures. Moreover, elderly individuals with a history of fragility fractures are at high risk of vertebral and hip fractures, so bisphosphonates, denosumab and teriparatide are well indicated in these patients...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28120114/longitudinal-patterns-of-bone-targeted-agent-use-among-patients-with-solid-tumors-and-bone-metastases-in-the-united-states
#18
Yi Qian, Debajyoti Bhowmik, Nandita Kachru, Rohini K Hernandez
PURPOSE: This study examined real-world long-term use of guideline-recommended bone targeted agents (BTA) among patients with metastatic solid tumors. METHODS: Adults with a solid tumor diagnosis followed by a bone metastasis diagnosis in 2012-2014 were identified from electronic medical records in the Oncology Services Comprehensive Electronic Records (OSCER) database. Patients initiated zoledronic acid (ZA) or denosumab on or after the bone metastasis diagnosis and were followed through last clinic visit by 30 June 2015...
January 24, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28109658/intra-articular-ectopic-ossification-associated-with-denosumab-administration-for-giant-cell-tumor-of-bone-with-intra-articular-pathological-fracture
#19
Eiji Osaka, Yuki Okamura, Yukihiro Yoshida, Masahiko Sugitani, Yasuaki Tokuhashi
No abstract text is available yet for this article.
January 18, 2017: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://www.readbyqxmd.com/read/28105885/denosumab-in-patients-with-giant-cell-tumor-of-bone-in-norway-results-from-a-nationwide-cohort
#20
Kjetil Boye, Nina Louise Jebsen, Olga Zaikova, Heidi Knobel, Ayca M Løndalen, Clement S Trovik, Odd R Monge, Kirsten Sundby Hall
BACKGROUND: Denosumab is a relatively new treatment option for patients with giant-cell tumor of bone (GCTB). The purpose of this study was to report the results for patients treated in Norway. MATERIALS AND METHODS: Patients treated with denosumab for GCTB were identified from the clinical databases at the Norwegian sarcoma reference centers. Data were retrieved from the clinical databases and supplemented by retrospective review of patient records. Denosumab was given as a subcutaneous injection every 4 weeks with loading doses on day 8 and 15 in cycle 1...
January 20, 2017: Acta Oncologica
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"